Comparative Pharmacology
Head-to-head clinical analysis: ALDURAZYME versus FABRAZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDURAZYME versus FABRAZYME.
ALDURAZYME vs FABRAZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALDURAZYME (laronidase) is a recombinant form of human α-L-iduronidase, an enzyme that hydrolyzes terminal α-L-iduronic acid residues in glycosaminoglycans (GAGs) such as dermatan sulfate and heparan sulfate. It replaces the deficient enzyme in patients with mucopolysaccharidosis I (MPS I), reducing lysosomal accumulation of GAGs.
Fabrazyme (agalsidase beta) is a recombinant human alpha-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal alpha-galactosyl residues, thereby reducing accumulation of these substrates in tissues.
0.58 mg/kg administered intravenously once weekly.
1 mg/kg intravenously every 2 weeks infused over 4-6 hours.
None Documented
None Documented
Terminal half-life: 6–10 minutes (rapid clearance from plasma due to cellular uptake via mannose-6-phosphate receptors); clinical context: clearance is saturable, leading to longer effective half-life at therapeutic doses
Terminal elimination half-life ranges from 80 to 120 minutes (1.3-2 hours) in adults, which supports a bi-weekly intravenous dosing regimen.
Renal: negligible; primarily catabolism via peptide hydrolysis; no significant biliary/fecal elimination
Primarily eliminated via renal pathways; 55-65% of the administered dose is recovered in urine as unchanged drug, with less than 5% recovered in feces.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy